Neurocrine Biosciences, Inc. - Common Stock (NBIX)

Record $1.1B revenue marks transformative quarter for diversified biotech.

Neurocrine Biosciences (NASDAQ:NBIX) reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines: INGREZZA, CRENESSITY and VYKAT XR. Chief Executive Officer Kyle Gano said the company’s commercial

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify beyond its largest product, INGREZZA. Gano said China has become both a com

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.

Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the company added a partial-quarter contribution from VYKAT XR following its acquisition of Soleno The

Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.